Evidence map›Paper›PMID 26047157›Full record

ArticlePLoS genetics2015

Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.

Mary J Emond, Tin Louie, Julia Emerson, Jessica X Chong, Rasika A Mathias, Michael R Knowles, Mark J Rieder, Holly K Tabor, Debbie A Nickerson, Kathleen C Barnes and 4 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00037765 (Gene Modifiers of Cystic Fibrosis Lung Disease), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00037765 active not recruitingnot on this map

Gene Modifiers of Cystic Fibrosis Lung Disease

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2001 to 2027Enrolled600ConditionsCystic Fibrosis, Lung Diseases
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Annals of the American Thoracic Society · 2025
    Article
  3. Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
  6. Pseudomonas aeruginosa in the Cystic Fibrosis Lung.Advances in experimental medicine and biology · 2022
    Article
  7. Mucosal Immunity in Cystic Fibrosis.Journal of immunology (Baltimore, Md. : 1950) · 2021
    Review
  8. Review
  9. Inflammasome Genetic Variants, Macrophage Function, and Clinical Outcomes in Cystic Fibrosis.American journal of respiratory cell and molecular biology · 2021
    Observational
  10. Review
  11. Article
  12. Article
  13. UnderstandingCells · 2020
    Review
  14. Observational
  15. Article
  16. Article
  17. The impact of host genetic background in the Pseudomonas aeruginosa respiratory infections.Mammalian genome : official journal of the International Mammalian Genome Society · 2018
    Review
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Mary J EmondDepartment of Biostatistics, University of Washington, Seattle, Washington, United States of America.
Tin LouieDepartment of Biostatistics, University of Washington, Seattle, Washington, United States of America.
Julia EmersonDepartment of Pediatrics, University of Washington, Seattle, Washington, United States of America; Center for Clinical and Translational Medicine, Seattle Children's Research Institute Seattle, Washington, United States of America.
Jessica X ChongDepartment of Pediatrics, University of Washington, Seattle, Washington, United States of America.
Rasika A MathiasDepartment of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Michael R KnowlesCystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Mark J RiederDepartment of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Holly K TaborDepartment of Pediatrics, University of Washington, Seattle, Washington, United States of America; Trueman-Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, Seattle, Washington, United States of America.
Debbie A NickersonDepartment of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
Kathleen C BarnesDepartment of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
NHLBI GO Exome Sequencing Project
Lung GoDepartment of Biostatistics, University of Washington, Seattle, Washington, United States of America.
Ronald L GibsonDepartment of Pediatrics, University of Washington, Seattle, Washington, United States of America; Division of Pulmonary Medicine, Seattle Children's Hospital, Seattle, Washington, United States of America.
Michael J BamshadDepartment of Pediatrics, University of Washington, Seattle, Washington, United States of America; Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America; Division of Genetic Medicine, Seattle Children's Hospital, Seattle, Washington, United States of America.
University of Washington · USSeattle Children's Hospital · USJohns Hopkins University · USSeattle Children's Hospital · USUniversity of North Carolina at Chapel Hill · US

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4M
Northwest Genomics CenterRC2HL102926 · NHLBI · UNIVERSITY OF WASHINGTON · PI GREEN, PHILIP P, NICKERSON, DEBORAH A · 2009 to 2009
$11.0M
Comprehensive Sequencing and Analysis of Variation in NHLBI CohortsRC2HL102925 · NHLBI · BROAD INSTITUTE, INC. · PI ALTSHULER, DAVID, GABRIEL, STACEY · 2009 to 2009
$10.2M
ARRA - NHLBI Lung Cohorts Sequencing ProjectRC2HL102923 · NHLBI · UNIVERSITY OF WASHINGTON · PI BAMSHAD, MICHAEL JOSEPH, BARNES, KATHLEEN C · 2009 to 2009
$2.6M
NHLBI NIH HHS RC2 HL102923NHLBI NIH HHS RC2 HL102925NHLBI NIH HHS RC2 HL102926NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

Discovery of rare or low frequency variants in exome or genome data that are associated with complex traits often will require use of very large sample sizes to achieve adequate statistical power. For a fixed sample size, sequencing of individuals sampled from the tails of a phenotype distribution (i.e., extreme phenotypes design) maximizes power and this approach was recently validated empirically with the discovery of variants in DCTN4 that influence the natural history of P. aeruginosa airway infection in persons with cystic fibrosis (CF; MIM219700). The increasing availability of large exome/genome sequence datasets that serve as proxies for population-based controls affords the opportunity to test an alternative, potentially more powerful and generalizable strategy, in which the frequency of rare variants in a single extreme phenotypic group is compared to a control group (i.e., extreme phenotype vs. control population design). As proof-of-principle, we applied this approach to search for variants associated with risk for age-of-onset of chronic P. aeruginosa airway infection among individuals with CF and identified variants in CAV2 and TMC6 that were significantly associated with group status. These results were validated using a large, prospective, longitudinal CF cohort and confirmed a significant association of a variant in CAV2 with increased age-of-onset of P. aeruginosa airway infection (hazard ratio = 0.48, 95% CI=[0.32, 0.88]) and variants in TMC6 with diminished age-of-onset of P. aeruginosa airway infection (HR = 5.4, 95% CI=[2.2, 13.5]) A strong interaction between CAV2 and TMC6 variants was observed (HR=12.1, 95% CI=[3.8, 39]) for children with the deleterious TMC6 variant and without the CAV2 protective variant. Neither gene showed a significant association using an extreme phenotypes design, and conditions for which the power of an extreme phenotype vs. control population design was greater than that for the extreme phenotypes design were explored.

Indexed as

ExomeGenes, ModifierPhenotypeAdolescentCaveolin 2ChildChild, PreschoolCystic FibrosisFemaleHumansMaleMembrane ProteinsPolymorphism, GeneticPseudomonas aeruginosaPseudomonas InfectionsCAV2 protein, humanCaveolin 2Membrane ProteinsTMC6 protein, human

Identifiers

PMID26047157
PMCPMC4457883
OpenAlexW1973719228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.